GlassScriptPhysician profile
Erin S Dice
NPI 1699953166
$12,842.47
in general payments reported to CMS, 2019-2025
26 companies · $2,896 in 2025
The $2,896 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $680 · 2022: $1,763 · 2023: $3,512 · 2024: $3,991 · 2025: $2,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,107 · Consulting Fee: $1,738 · Education: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,106.87 |
| Consulting Fee | $1,738.00 |
| Education | $554.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,262.03 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,722.90 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,352.94 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,291.41 | 2022-2025 | Sotyktu, Sprycel |
| Novartis Pharmaceuticals Corporation | $990.79 | 2021-2025 | |
| Medimetriks Pharmaceuticals, INC. | $727.69 | 2022-2025 | Clindacin Etz, Neuac, Neo-Synalar |
| Sun Pharmaceutical Industries INC. | $707.99 | 2021-2025 | Winlevi, Ilumya |
| Genzyme Corporation | $692.14 | 2022-2025 | |
| Pfizer INC. | $539.84 | 2022-2025 | |
| Lilly USA, LLC | $510.55 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Scientific Affairs, LLC | $265.45 | 2022-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $218.84 | 2023-2024 | Dupixent |
| Galderma Laboratories, L.P. | $209.41 | 2021-2024 | Aklief, Epsolay, Oracea |
| Arcutis Biotherapeutics, INC. | $198.25 | 2024-2025 | Zoryve |
| Journey Medical Corporation | $161.11 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $159.42 | 2022-2024 | Adbry |
| Mayne Pharma Commercial LLC | $144.26 | 2022-2025 | |
| Dermavant Sciences, INC. | $137.69 | 2023 | Vtama |
| Amgen INC. | $136.42 | 2021-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $98.99 | 2025 | |
| Incyte Corporation | $90.81 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $80.87 | 2022-2025 | Cabtreo |
| Cipher Pharmaceuticals US LLC | $69.99 | 2025 | Natroba, Spinosad |
| Almirall LLC | $39.08 | 2023-2025 | Klisyri |
| Organon LLC | $20.43 | 2025 | Vtama |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Dice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.